Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
InhaleRx Limited ( (AU:IRX) ) has shared an announcement.
InhaleRx Limited has received Human Research Ethics Committee approval for its redesigned IRX-211 Phase 2 trial, which now features an expanded scope and improved design to enhance statistical significance. This approval, granted without queries and ahead of schedule, positions the company to accelerate its clinical program, potentially bypassing a separate Phase 3 trial. The company has already secured manufacturing and stability testing, with patient dosing expected to begin in Q3 2025, thereby advancing IRX-211’s development and potentially delivering earlier value to patients and shareholders.
More about InhaleRx Limited
InhaleRx Limited is an Australian drug development company focused on creating unique medicinal drug-device products for unmet medical needs in pain management and mental health. The company aims to achieve U.S. FDA approval through rapid and cost-effective regulatory pathways, targeting conditions like Breakthrough Cancer Pain and Panic Disorder.
Average Trading Volume: 216,688
Technical Sentiment Signal: Hold
Current Market Cap: A$6.4M
For a thorough assessment of IRX stock, go to TipRanks’ Stock Analysis page.